Personal finance
Burger King slims down for success
The Penguin-Random House merger: 3 takeaways
Dunkin' weathers storm to attract crowds
Inside Wall Street: Bank weathers its own storm
How Sandy will affect shipping business
The whopping US rally that wasn't
Disney acquires Lucasfilm for $4B
Late-inning earnings plays
Gilead's 'son of Viread' passes first test
Auto sales expected to stay strong into 2013
Why Yamana shares are soaring
Archer Daniels Midland is boring and cheap
Stericycle finds treasure in trash
Don't follow Icahn into Netflix
How to trade the US presidential election
David Einhorn is shorting iron ore
What's next for Exxon after Rosneft buy?
Who's right, Main Street or Wall Street?
Hershey shareholders sue for child labor records
China's growth picks up
Europe offsets Johnson Controls' Asia gains
CSX took too heavy a beating
In retail, pessimism doesn't pay
Illumina should reconsider Roche's offer
Illumina should reconsider Roche's offer
Perhaps it's in the best interests of shareholders if Illumina (ILMN +1.76%) reverses course and lets Roche Holding AG (RHHBY -0.57%) know it's amenable to a buyout. Because maybe the only factor propping up the shares of Illumina, maker of gene sequencing equipment, is the prospect of a better offer from the Swiss health care giant.

Roche has proposed purchasing Illumina in the past year, but up to now, to paraphrase the TV game show, "The Price Hasn't Been Right." Despite the brush off, Roche isn't giving up. The company said it still wants to add gene sequencing to its product portfolio and is looking at possible deals, according to an Oct. 16 article in Bloomberg.

Roche's motivation is clear: access to a potentially huge and lucrative market. By 2017, the bioinformatics market size is expected to reach $9.1 billion. Considering genomic interpretation makes up the largest segment of bioinformatics, that means about $7.7 billion will be spent in this specific area in 2017, said an article in Genetic Engineering and Biotechnology News earlier this year.

The hope is that by that time gene sequencing will become a mainstay in clinical testing -- paid for by insurers -- rather than what it is now, essentially a research tool.

Despite some shareholder disappointments in the past, Illumina remains the leading gene sequencing company. The company's shares are up nearly 50% this year, but the stock price has declined about 9% in the past three weeks, maybe due to its opposition to a marriage with Roche.

An expected drop in government and academic funding also may have hurt investor confidence, which is one reason the company "tightened" its 2012 guidance ranges for both revenue and earnings per share. Investors who want to learn exactly how to trade a stock like Illumina can get the information they need in our real time trading reports.

Will Roche look elsewhere after being rebuffed by Illumina, or is it just bluffing? One of its alternate targets could be Life Technologies (LIFE -0.06%), which is expected to earn $3.95 per share in 2012 on sales of nearly $3.8 billion. Shares are up more than 20% in 2012 and now trade just off the company's 52-week high of $50.99.

Another industry competitor, Luminex (LMNX -2.07%), would certainly be cheaper than either Illumina or Life Technologies given its substantially lower market cap. But Roche couldn't like the fact that Luminex recently reported lower third-quarter earnings, missing estimates on both revenue and earnings per share.

Last, and undoubtedly least, is Affymetrix (AFFX -2.69%), which has been around since 1992. Once a high-flier among gene sequencing companies, Affymetrix today trades at just above $3, a far cry from the $144 share price it commanded in 2000.

Considering all the options, it's fairly certain that Roche isn't giving up on buying Illumina. It seems to be a simple matter of when, not if, and at what price.

For more information on stocks in this space, our real time trading reports help investors identify opportunities before they happen.

Для печати
Microsoft will 'die and disappear' in next few years
Whole Foods' freshness starting to wilt
In a war of attrition, Microsoft will beat Apple again
Asbury Automotive sees strong earnings momentum
Student debtors get the runaround
What to keep in your money survival kit
First-date coupon use is on the rise
Groupon offers NYC dinner in the dark
The worst credit cards of 2012
Post-Sandy, banks waive fees
Homeowners spared costly hurricane deductible
7 ways to commit financial suicide
Why are car loans so easy to get?
Best credit cards after bankruptcy
Get more cash for your old clothes
5 fee-free ways to help Sandy victims
After a flood, frugality can be dangerous
After the storm: Rebuild or move?
My unexpected $2,400 vet bill
Best credit cards for holiday shopping
Downside of a higher retirement age
Prepaid cards are not gift cards
Is the economy destroying love?
Financial lesson from a football game
Book Christmas flights before Black Friday
6 ways to earn extra holiday cash
Holiday shopping? Avoid this retail trick
Many holding out for Cyber Monday
SiriusXM drives straight race to $3 a share
Sandy: Beware the bubble in storm stocks
Starbucks: Buy it, own it, love it
4 Canadian value stocks
What's the White House worth?
Stocks are immune to Washington
EMC strengthens RSA business with acquisition
Russia garners another favorable valuation call
Goldman Sachs slashes partnership ranks
Inside Wall Street: Cheers from Bud and Diageo
4 favorites for a housing rebound
Is Baidu's China reign over?
In 2013, Apple, Facebook will fly, Intel will die
Is AOL's turnaround for real?
Stock buyback blitz continues
Anheuser-Busch pushes higher-alcohol beers
Baidu: Searching for growth in China
Twitter vs. Facebook: The war heats up
Would Disney buy Hasbro?
Vending-machine pizza prepares for US debut
Amazon lockers coming to Staples
Are customers becoming less loyal to Apple?
Focus on earnings, not fiscal cliff
Evergreen stocks: 4 favorite dividend ideas
Visit Statistics